These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9049859

  • 1. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG, Rice CD, Tuttle TM, Bear HD, Hirsch JI, Merchant RE.
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [Abstract] [Full Text] [Related]

  • 2. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
    Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE.
    J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
    [Abstract] [Full Text] [Related]

  • 3. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD.
    Cancer Res; 1992 Feb 01; 52(3):548-53. PubMed ID: 1732041
    [Abstract] [Full Text] [Related]

  • 4. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD.
    Cancer Immunol Immunother; 2009 Oct 01; 58(10):1565-76. PubMed ID: 19198835
    [Abstract] [Full Text] [Related]

  • 5. Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
    Haynes C, Graham L, Bear HD.
    Methods Cell Biol; 2024 Oct 01; 183():355-380. PubMed ID: 38548419
    [Abstract] [Full Text] [Related]

  • 6. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M, Plautz GE, Shu S.
    Cancer Res; 1996 Oct 15; 56(20):4702-8. PubMed ID: 8840987
    [Abstract] [Full Text] [Related]

  • 7. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep 15; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 8. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
    Tuttle TM, Inge TH, McCrady CM, Bethke KP, Bear HD.
    J Immunother (1991); 1992 Jul 15; 12(1):32-40. PubMed ID: 1386251
    [Abstract] [Full Text] [Related]

  • 9. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
    Cha E, Graham L, Manjili MH, Bear HD.
    Breast Cancer Res Treat; 2010 Jul 15; 122(2):359-69. PubMed ID: 19826947
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP, Heitz T, Wood GW.
    J Neurosurg; 1992 Nov 15; 77(5):757-62. PubMed ID: 1403119
    [Abstract] [Full Text] [Related]

  • 11. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS, Graham LJ, Hamad GG, George KR, Bear HD.
    J Surg Res; 2001 Jun 15; 98(2):108-15. PubMed ID: 11397126
    [Abstract] [Full Text] [Related]

  • 12. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.
    Plautz GE, Touhalisky JE, Shu S.
    Cell Immunol; 1997 Jun 15; 178(2):101-7. PubMed ID: 9225000
    [Abstract] [Full Text] [Related]

  • 13. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX, Chen BG, Plautz GE.
    J Immunol; 2002 Sep 15; 169(6):3314-20. PubMed ID: 12218152
    [Abstract] [Full Text] [Related]

  • 14. Precursor frequency analysis of bryostatin activated lymphocytes.
    Fleming MD, Barrett SK, Bear HD.
    J Surg Res; 1994 Jul 15; 57(1):74-9. PubMed ID: 8041153
    [Abstract] [Full Text] [Related]

  • 15. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro.
    Fleming MD, Bear HD, Lipshy K, Kostuchenko PJ, Portocarero D, McFadden AW, Barrett SK.
    J Immunother Emphasis Tumor Immunol; 1995 Oct 15; 18(3):147-55. PubMed ID: 8770770
    [Abstract] [Full Text] [Related]

  • 16. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H.
    Gene Ther; 2004 Nov 15; 11(21):1551-8. PubMed ID: 15343358
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.
    Merchant RE, Baldwin NG, Rice CD, Bear HD.
    Neurol Res; 1997 Apr 15; 19(2):145-52. PubMed ID: 9175143
    [Abstract] [Full Text] [Related]

  • 18. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S.
    Clin Cancer Res; 2000 Jun 15; 6(6):2209-18. PubMed ID: 10873070
    [Abstract] [Full Text] [Related]

  • 19. Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats.
    Wood GW, Turner T, Wang YY, Holladay FP.
    J Immunother; 1999 Nov 15; 22(6):497-505. PubMed ID: 10570748
    [Abstract] [Full Text] [Related]

  • 20. Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.
    Zoon CK, Wan W, Graham L, Bear HD.
    Int J Mol Sci; 2017 Jan 29; 18(2):. PubMed ID: 28146052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.